$CAH

Jim Cramer’s “top 10 things to watch” covers July CPI (headline 3.4% YoY, core 2.5%), with 2-year Treasury yields moving lower. He also cites stock moves and analyst actions: CoreWeave up ~19% on results, Super Micro target boosts to $39, Aramark target to $71, Cardinal Health target raised, Intuitive Surgical upgraded, Palo Alto Networks target to $415, Novo Nordisk downgraded, and On Holding removed after guidance cuts.

U.S. indexes drifted lower as crude oil and interest rates were mostly flat, with investors awaiting the July CPI report. FactSet data for 88% of S&P 500 firms showed 86% positive earnings surprises and 76% positive revenue surprises. Nasdaq fell 0.6% to 26,445, S&P 500 0.3% to 7,728, Dow 0.3% to 53,791. CoreWeave (CRWV) and Super Micro (SMCI) report after the close; Nvidia (NVDA) and Intel (INTC) were also discussed.

Cardinal Health (CAH) reported fiscal 2026 Q4 results for the three months ended June 30. Revenue rose about 6% to $63.67B, below LSEG’s $65.03B estimate. Adjusted EPS was $2.60 vs $2.42 consensus, excluding a 31-cent tariff-refund benefit. The firm raised its price target to $265 from $245 and kept a hold-equivalent 2 rating.

US stocks fell modestly as oil prices rose on uncertainty around the Strait of Hormuz. The S&P 500 was down 0.4%, Nasdaq 0.8%, and ASX futures pointed to a 0.5% drop at the open. Brent traded around $88.71. Investors awaited US inflation data and a possible Fed rate move, while companies including Cardinal Health, Aramark, On Holding, and Intel reported results or guidance.

Cardinal Health’s fiscal 2026 performance was supported by resilient demand in Pharmaceutical and Specialty Solutions, with Specialty strength growing over 25% and a $100 million net nonrecurring GMPD tailwind from IEEPA tariff refunds. For fiscal 2027, it guided EPS of $12.40 to $12.60, with GMPD profit $200 million to $220 million, plus $700 million CapEx and at least $1 billion share repurchases.

Cardinal Health (CAH) reported Q4 FY2026 revenue of $63.7B, up 6% year over year. GAAP diluted EPS rose to $1.70 from $1.00, and non-GAAP diluted EPS to $2.91 from $2.08. FY2026 revenue increased to $254.2B, up 14%, with non-GAAP diluted EPS at $11.26. FY2027 non-GAAP EPS guidance is $12.40 to $12.60, and the board approved a $0.5158 quarterly dividend.

U.S. stocks were slightly lower, with the S&P 500 down 0.3%, as oil prices swung on uncertainty about when crude flows will resume after the Iran conflict. Brent moved from above $90 to below $87, last at $88.77. AAA said regular gasoline averaged $4.01. Investors await U.S. inflation data and Fed rate expectations.

Jim Cramer’s Aug. 11 “top 10” watchlist highlights: rising Treasury yields (10-year above 4.7%, 30-year near 5.28%) tied to Iran-related oil concerns; Intel raising a $20B secondary stock sale at $95; Nvidia’s $500B AI financing initiative; Riot Platforms up on a $9B compute deal with Anthropic; UBS upgrading Jabil to buy; and earnings or analyst actions for Cardinal Health, Apple, Gap, and Allstate (Citi PT raised to $240).

Cardinal Health forecast fiscal 2027 adjusted profit per share of $12.40 to $12.60, above the $12.04 average estimate, citing strength in specialty drugs. In Q4, adjusted profit was $2.91 per share versus $2.42 expected, while revenue rose 6% to $63.67B, below $65.03B. The company also plans $1B share repurchases in FY2027.

Premarket movers included Intel, Hims & Hers Health, Riot Platforms, Plug Power, First Solar, Cardinal Health, and On Holding. Intel fell after upsizing a common stock offering to $20B. Hims & Hers shares dropped after trimming full-year EBITDA guidance and reporting a Q2 net loss. Riot rose on Q2 revenue above estimates. First Solar got a Baird upgrade with a $318 target. Cardinal Health edged up on EPS beat but revenue miss. On Holding fell after mixed results and lower revenue guidance.